CareDx Announces CMS Retires Draft Policy Restricting Coverage, Restoring Longstanding Coverage For AlloSure, AlloMap, And HeartCare Through Surveillance Testing For Allograft Rejection
Portfolio Pulse from Benzinga Newsdesk
CareDx announced that the Centers for Medicare & Medicaid Services (CMS) has retired a draft policy that would have restricted coverage for its AlloSure, AlloMap, and HeartCare tests. The longstanding coverage for these tests, which are used for surveillance testing for allograft rejection, has been restored.
August 16, 2024 | 6:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CareDx announced that CMS has retired a draft policy that would have restricted coverage for its AlloSure, AlloMap, and HeartCare tests. The longstanding coverage for these tests has been restored, which is positive news for the company.
The restoration of longstanding coverage by CMS for CareDx's key tests (AlloSure, AlloMap, and HeartCare) removes a significant regulatory risk and is likely to positively impact the company's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100